CDC’s 2012 Tips From Former Smokers campaign helped more than 100,000 Americans quit smoking
ATLANTA — The Centers for Disease Control and Prevention’s 2012 Tips From Former Smokers campaign helped more than 100,000 Americans likely quit smoking for good, exceeding the original goal of 50,000, the agency announced Wednesday.
The 2013 Tips campaign generated 150,000 additional calls to quitlines and 2.8 million additional website visits.
"The Tips from Former Smokers campaign shows the painful effects of smoking through former smokers, in a way that numbers alone cannot,” stated CDC director Tom Frieden. “These are the kinds of ads that smokers tell us help motivate them to quit, saving lives and money.”
This January will mark the 50th anniversary of the first Surgeon General’s Report linking cigarette smoking to lung cancer.
Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
CHICAGO — Among patients with mild to moderate Alzheimer disease, a daily dosage of 2,000 IUs of vitamin E, compared to placebo, was effective in slowing functional decline and in reducing caregiver time in assisting patients, according to a study that appeared in the Jan. 1 issue of the Journal of the American Medical Association.
"These results point to a powerful role of integrating proper nutrition into disease management, and provide hope for Alzheimer’s patients and their care givers," saidd Duffy MacKay, VP scientific and regulatory affairs for the Council for Responsible Nutrition. "However, the dietary supplement industry should be reminded that dietary supplements cannot be marketed or sold to consumers as a disease treatment, and we recommend that those suffering with Alzheimer’s disease rely on the advice of a trusted doctor as to the appropriate treatment plan. Self-dosing at the levels studied in this trial are not recommended."
Alpha tocopherol, a fat-soluble vitamin and antioxidant, has been studied in patients with moderately severe Alzheimer disease and in participants with mild cognitive impairment, but has not been studied in patients with mild to moderate AD. In patients with moderately severe AD, vitamin E was shown to be effective in slowing clinical progression.
The drug memantine has been shown to be effective in patients with AD and moderately severe dementia, according to background information in the article.
Maurice Dysken of the Minneapolis VA Health Care System and colleagues examined the effectiveness and safety of vitamin E, memantine and the combination for treatment of functional decline in patients with mild to moderate AD who were taking an acetylcholinesterase inhibitor (a chemical that increases the level and duration of action of the neurotransmitter acetylcholine). The trial included 613 patients at 14 Veterans Affairs medical centers.
Over the average follow-up time of 2.3 years, participants receiving vitamin E had slower functional decline than those receiving placebo, with the annual rate of decline in ADLs reduced by 19%. This treatment effect translates into a clinically meaningful delay in progression in the vitamin E group of 6.2 months.
Neither memantine nor the combination of vitamin E and memantine showed clinical benefit in this trial.
In addition, caregiver time was reduced by about two hours per day in the vitamin E group.
FDA cracks down on illegal concussion claims
SILVER SPRING, Md. — The Food and Drug Administration is cracking down on companies claiming their products can speed recovery from concussions, according to a consumer update posted Wednesday.
"The Food and Drug Administration is monitoring the marketplace and taking enforcement actions where appropriate, issuing warning letters to firms — the usual first step for dealing with claims that products labeled as dietary supplements are intended for use in the cure, mitigation, treatment or prevention of disease," the agency stated. "The agency also is warning consumers to avoid purported dietary supplements marketed with claims to prevent, treat or cure concussions and other traumatic brain injuries because the claims are not backed with scientific evidence that the products are safe or effective for such purposes. These products are sold on the Internet and at various retail outlets, and are marketed to consumers using social media, including Facebook and Twitter."
One common claim is that a particular dietary supplement promotes faster healing times after a concussion or other TBI. "Even if a particular supplement contains no harmful ingredients, that claim alone can be dangerous," stated Gary Coody, FDA’s National Health Fraud Coordinator. "We’re very concerned that false assurances of faster recovery will convince athletes of all ages, coaches and even parents that someone suffering from a concussion is ready to resume activities before they are really ready," he said. "Also, watch for claims that these products can prevent or lessen the severity of concussions or TBIs."
A growing body of scientific evidence indicates that if concussion victims resume strenuous activities — such as football, soccer or hockey — too soon, they risk a greater chance of having a subsequent concussion. Moreover, repeat concussions can have a cumulative effect on the brain, with consequences that can include brain swelling, permanent brain damage, long-term disability and death.
"As amazing as the marketing claims here are, the science doesn’t support the use of any dietary supplements for the prevention of concussions or the reduction of post-concussion symptoms that would enable one to return to playing a sport faster," added Daniel Fabricant, director of FDA’s Division of Dietary Supplement Programs.
One of the first alarms raised about dietary supplements being promoted to treat TBI came from the U.S. Department of Defense. "We first learned from the military about a product being marketed to treat TBI, obviously a concern with wounded veterans. We were taken aback that anyone would make a claim that a supplement could treat TBI, a hot-button issue," said Jason Humbert, a senior regulatory manager with FDA’s Office of Regulatory Affairs. "That sparked our surveillance."
Typically, products promising relief from TBIs tout the benefits of such ingredients as turmeric and high levels of omega-3 fatty acids derived from fish oil.
In December 2013, FDA issued a warning letter to Star Scientific for marketing its product Anatabloc with claims to treat TBIs.